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http:WHAT THIS PAPER ADDS
The International Carotid Stenting Study (ICSS) compared carotid artery stenting (CAS) with endarterectomy for
stroke prevention in patients with recently symptomatic carotid artery stenosis. The aim of the present study
was to determine if there were speciﬁc factors related to CAS procedures, the process of care, or baseline
patient characteristics that signiﬁcantly increased or decreased the risk of stroke, myocardial infarction, or death
within 30 days of CAS in ICSS. It was found that increasing age independently increased the risk of CAS, while the
risk was signiﬁcantly lower in patients undergoing a right-sided procedure, in patients taking the combination of
aspirin and clopidogrel, and in those presenting only with amaurosis fugax. Cerebral protection device use did
not modify the risk, but the risk was signiﬁcantly higher in patients treated with an open-cell stent compared to
a closed-cell stent.Objectives: Stroke, myocardial infarction (MI), and death are complications of carotid artery stenting (CAS). The
effect of baseline patient demographic factors, processes of care, and technical factors during CAS on the risk of
stroke, MI, or death within 30 days of CAS in the International Carotid Stenting Study (ICSS) were investigated.
Methods: In ICSS, suitable patients with recently symptomatic carotid stenosis > 50% were randomly allocated
to CAS or endarterectomy. Factors inﬂuencing the risk of stroke, MI, or death within 30 days of CAS were
examined in a regression model for the 828 patients randomized to CAS in whom the procedure was initiated.
Results: Of the patients, 7.4% suffered stroke, MI, or death within 30 days of CAS. Independent predictors of risk
were age (risk ratio [RR] 1.17 per 5 years of age, 95% CI 1.01e1.37), a right-sided procedure (RR 0.54, 95% CI
0.32e0.91), aspirin and clopidogrel in combination prior to CAS (compared with any other antiplatelet regimen,
RR 0.59, 95% CI 0.36e0.98), smoking status, and the severity of index event. In patients in whom a stent was
deployed, use of an open-cell stent conferred higher risk than use of a closed-cell stent (RR 1.92, 95% CI 1.11e
3.33). Cerebral protection device (CPD) use did not modify the risk.
Conclusions: Selection of patients for CAS should take into account symptoms, age, and side of the procedure.
The results favour the use of closed-cell stents. CPDs in ICSS did not protect against stroke.
 2015 The Authors. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Carotid artery stenting (CAS) is an endovascular alternative
to carotid endarterectomy (CEA) for the treatment of
symptomatic atherosclerotic disease of the carotid artery.
The International Carotid Stenting Study (ICSS) was a large
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Figure 1. Univariable predictors of the risk of stroke, myocardial infarction or death within 30 days of carotid artery stenting in 828 ICSS
per-protocol participants in whom the procedure was initiated.* Only patients with a protection device. ** Only patients were a stent was
deployed. Patients with missing data were excluded for each relevant analysis. Variables with >1% missing data are: stent cell design (3%),
any pre-procedure antiplatelet (8%), aspirin and clopidogrel pre-procedure (8%), any pre-procedure anticoagulant (8%), any post-
procedure antiplatelet (8%), any post-procedure anticoagulant (8%), baseline Rankin score (2%), duration of CAS (17%), baseline
systolic BP (6%), baseline diastolic BP (6%), and cholesterol (14%).
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Figure 1. (continued).
Risk of Stroke, MI or Death after Carotid Stenting 329randomized controlled open clinical trial that compared the
efﬁcacy and safety of CAS and CEA in patients with recently
symptomatic carotid stenosis measuring greater than 50%.
In an interim analysis, the risk of stroke, myocardial infarc-
tion (MI), or death within 30 days of the procedure was
higher for those patients who received their allocated CAS
procedure than for those who received their allocated CEA
procedure (7.4% vs. 4.0%, p ¼ .003).1 Haemodynamic
disturbance, carotid embolism and thrombosis or occlusionof the carotid artery were all important mechanisms of
ischaemic stroke in these patients.2
The optimal stenting technique, patient selection, and
processes of care for CAS have yet to be determined.
Endovascular carotid revascularization is a complex proce-
dure requiring attention to pre-procedure medication, intra-
and post-procedure haemodynamic control, stent design,
and optimal medical therapy.3 The additional use of cere-
bral protection devices (CPDs), intended to catch debris
330 D. Doig et al.arising from the plaque or dislodged thrombus to prevent
distal embolization, has become more common in recent
years4 despite conﬂicting evidence supporting their routine
use.
The patients recruited to ICSS were examined to deter-
mine whether there are speciﬁc CAS procedures, processes
of care or baseline patient characteristics associated with a
higher risk of stroke, MI, or death within 30 days of the
procedure.METHODS
Study design
Patient selection and protocol design. Details of the ICSS
trial protocol are published elsewhere.5 In brief, clinically
stable patients over 40 years old were eligible for
randomization in ICSS if they had more than 50% recently
symptomatic carotid stenosis suitable for either CAS or CEA.
Patients were excluded if they had a major stroke with poor
recovery, if their vascular anatomy rendered CAS or CEA
unsuitable, if the stenosis was due to non-atheromatous
disease, if cardiac bypass was planned within 1 month of
the revascularization, or if there had been previous revas-
cularization of the symptomatic artery.
Stenting was performed in accordance with strict proto-
col; the stents and protection devices used were required to
be CE marked and approved by the trial steering committee,
and a CPD was recommended whenever the operator
thought one could safely be deployed. Centres and in-
terventionists were accredited by the trial steering com-
mittee. Centres not fulﬁlling the trial protocol requirements
for prior experience were permitted to join the trial as a
“supervised” centre: procedures were supervised by a more
experienced interventionist at these sites. The combination
of the antiplatelet agents aspirin and clopidogrel prior to
the procedure was recommended, and the administration
of intra-procedural heparin was mandatory.
The Northwest Multicentre Research Ethics Committee in
the UK approved ICSS. Participating centres obtained site-
speciﬁc approval. Patients provided written informed
consent.
Outcome events. A CAS technical data form was completed
by investigators and returned to the central trial ofﬁce.
Stroke, MI, or death occurring within 30 days of the pro-
cedure was reported by investigators and conﬁrmatory ev-
idence was required to be submitted (brain imaging, ECG,
cardiac enzymes, and/or death certiﬁcate where available).
Stroke was deﬁned as “an acute disturbance of focal
neurological function with symptoms lasting more than 24
hours resulting from intracranial vascular disturbance”. A
diagnosis of MI required two of the following criteria: car-
diac enzymes more than twice the upper limit of normal, a
history of chest discomfort for more than 30 minutes, or the
development of speciﬁc ECG abnormalities. Outcome
events were reported in detail to the central ofﬁce by the
local neurologist or stroke physician. Investigators at the
trial ofﬁce adjudicated the timing and cause of events byreview of evidence either from witnesses or case note re-
view at the centre involved. Major outcome events were
submitted to an independent external adjudicator, who was
masked to treatment allocation and who determined the
cause, severity, and duration of the event. If this assess-
ment differed from the initial assessment, a second external
adjudicator reviewed the event and any differences were
resolved by consensus.
Role of the funding source. The funders and sponsors of the
study had no role in study design, data collection, data
analysis, data interpretation, or the writing of this paper.
Statistical analysis. The data were analysed per-protocol,
that is only CAS patients in ICSS in whom the randomly
allocated procedure was initiated were included. A proce-
dure was deemed to have been initiated if the patient
underwent either local or general anaesthesia prior to
commencement of the procedure. Patients who crossed
over to CAS, received CAS after an attempt at endarterec-
tomy or received medical therapy instead of CAS were
excluded. Risk factors for stroke, MI, or death within 30 days
of the procedure were examined using binomial regression.
Patients with missing data were excluded from each rele-
vant analysis. To examine the effects of the use of CPD type,
stent design, and post-stent dilation only patients in whom
a CPD or stent was deployed were analysed. A multivariable
model was primarily developed using only those variables
potentially available for all CAS patients (i.e. excluding ce-
rebral protection device type, stent design and post-dilation
variables) using a forward stepwise approach. A p value of
<.05 was accepted as conferring statistical signiﬁcance in all
analyses. In sensitivity analysis, the multivariable model was
reconstructed excluding patients in whom a stent was not
deployed in order to be able to assess the effect of stent
design and post-dilation variables, and by excluding patients
in whom a CPD was not used to assess the effect of CPD
type. Analyses were performed using Stata (StataCorp.
2011. Stata Statistical Software: Release 12. College Station,
TX: StataCorp LP).RESULTS
Patient and procedure characteristics
A total of 1,713 patients were randomized in ICSS. Of the
853 assigned to CAS, 828 procedures were initiated per
protocol and were included in this analysis. There were
more men (70.4%) than women and just over half of the
patients were over the age of 70 (53.5%). Baseline char-
acteristics of the patient are given in Fig. 1. Summary sta-
tistics for continuous variables in the analysis are detailed in
Table 1. A stent was deployed in 764 of 816 procedures
(92.2%) for which data were available. The type of stent was
recorded in 752 of those procedures. In 367 (48.8%) pro-
cedures an open-cell stent was used, and in 371 (49.3%) a
closed-cell stent was used. Individual stent types are listed
in Table 2. A CPD was known to have been deployed in 585
(70.6%) procedures, of which 464 (79.3%) were known to
Table 4. Independent predictors of risk of stroke, MI or death
within 30 days of carotid artery stenting in 748 ICSS per-protocol
participants in whom the procedure was initiated and for whom
complete predictor data are available. Results obtained from
multivariable binomial regression.
Table 2. Design and types of stent used in ICSS.
Design and type of stent Number of patients
Stent deployed 764
Closed cell 371
Wallstent 318
XACT 48
Invatec 5
Open cell 367
Cordis 209
EV3 82
Acculink 70
XPONENT 3
NEXSTENT 3
Unknown type 26
Stent not deployed 64
Table 1. Summary statistics for baseline age, systolic blood
pressure, diastolic blood pressure, total cholesterol and time
from event to index procedure in 828 patients undergoing CAS
(mean [SD] unless otherwise stated).
Patient characteristic No. events/
no. patientsa
Mean (SD) or
median (IQR)
Baseline age in years 61/828 70 (9)
Baseline systolic blood
pressure in mmHg
58/781 147 (24)
Baseline diastolic blood
pressure in mmHg
58/781 79 (12)
Baseline total cholesterol
in mmol/L
55/715 4.8 (1.3)
Time index event to procedure
in days (median [IQR])
61/828 35 (15, 82)
Duration of CAS in minutes
(median [IQR])
55/684 60 (49.5, 80)
IQR ¼ interquartile range; SD ¼ standard deviation.
a Patients with available data.
Risk of Stroke, MI or Death after Carotid Stenting 331be distal ﬁlter type devices; 71.7% of patients were known
to be taking aspirin and clopidogrel in combination.Variable No. events/
no. patientsa
Adjusted risk
ratio (95% CI)
Global
p
Age (per 5 years
increase)
59/748 1.17 (1.01e1.37) .039
Smoking status
Never 23/207 1.00 .030
Former 31/359 0.86 (0.52e1.43)
Current 5/182 0.33 (0.13e0.85)
Nature of ipsilateral index event
Stroke 31/347 1.00 .019Timing and cause of events up to 30 days after the
procedure
Sixty-one of the 828 patients (7.4%) suffered stroke, MI, or
death within 30 days of the procedure. The nature of the
outcome events, the majority of which were stroke, are
listed in more detail in Table 3. Forty-four of the 61 (72.1%)
events occurred on the day of the procedure.Table 3. Type of outcome event occurring within 30 days of carotid
stenting in patients who received their allocated procedure.
Any stroke 58a
Ischaemic stroke 56
Haemorrhagic stroke 2
Fatal myocardial infarction within 30 days 3a
Non-fatal myocardial infarction 0
Death unrelated to stroke or myocardial
infarction
1
a One patient had both stroke and subsequent fatal myocardial
infarction.Demographic and technical risk factors
The results of univariable analysis are presented in Fig. 1.
The effect of age, analysed as a continuous variable in years,
was an increase in risk of 1.24 for each 5 years (95% CI
1.07e1.42, p ¼ .003). An increased risk of stroke, MI, or
death was observed in patients with an open design of
carotid stent (RR 1.86, 95% CI 1.09e3.19, p ¼ .024) and in
patients with atrial ﬁbrillation (RR 2.31, 95% CI 1.16e4.61,
p ¼ .017). The risk was lower in patients who were current
or former smokers at the time of enrolment compared with
those who had never smoked (RR 0.25, 95% CI 0.10e0.63
and RR 0.77, 95% CI 0.46e1.29 respectively, global
p ¼ .003), and those with amaurosis fugax as the initial
event prompting enrolment in the trial compared with
those who suffered stroke as the index event (RR 0.25, 95%
CI 0.08e0.79, global p ¼ .005). The risk was also lower in
those undergoing a right-sided procedure (RR 0.54, 95% CI
0.32e0.91, p ¼ .019). Other demographic or technical
factors did not signiﬁcantly affect the risk. Patients in whom
a CPD was used (n ¼ 585) experienced a higher risk of
events compared with those that did not (n ¼ 239) (RR
1.86, 95% CI 0.98e3.1, p ¼ .056), but this difference did not
reach statistical signiﬁcance. Patients treated in centres that
enrolled more than 50 patients were at lower risk of an
event (RR 0.60, 95% CI 0.37e0.96, p ¼ .035), but the results
in supervised centres (where procedures performed by
more inexperienced interventionists were proctored) were
not statistically different from those at experienced centres.
A multivariable model investigating variables potentially
available for all CAS patients is presented in Table 4.Retinal stroke 5/24 2.47 (1.11e5.52)
TIA 20/242 0.99 (0.58e1.68)
Amaurosis fugax 3/135 0.32 (0.10e1.02)
Side of procedure
Left 40/394 1.00 .020
Right 19/354 0.54 (0.32e0.91)
Antiplatelet regimen pre-procedure
Any other
antiplatelet
19/165 1.00 .042
Aspirin and
clopidogrel in
combination
40/583 0.59 (0.36e0.98)
a Patients with data available included in the multivariable model.
Table 5. Results of sensitivity analysis in 725 ICSS per-protocol
participants in whom the procedure was initiated and a stent
was deployed and for whom complete predictor data are
available. Results obtained from multivariable binomial regression.
Variable No. events/
no. patientsa
Adjusted risk
ratio (95% CI)
Global
p
Age (per 5 years
increase)
52/725 1.17 (1.00e1.38) .055
Smoking status
Never 21/196 1.00 .024
Former 27/322 0.80 (0.47e0.38)
Current 4/180 0.28 (0.10e0.81)
Nature of ipsilateral index event
Stroke 28/330 1.00 .013
Retinal stroke 4/22 2.33 (0.91e5.94)
TIA 18/242 0.97 (0.55e1.70)
Amaurosis fugax 2/131 0.22 (0.05e0.91)
Side of procedure
Left 34/378 1.00 .056
Right 18/347 0.59 (0.34e1.01)
Stent cell design
Closed 18/365 1.00 .019
Open 34/360 1.92 (1.11e3.33)
a Patients with data available included in the multivariable model.
332 D. Doig et al.Increasing age was found to increase the risk of stroke, MI,
or death within 30 days of the procedure after adjustment
for other variables in the model (RR 1.17 per 5 years of age,
95% CI 1.01e1.37, p ¼ .039). The risk was decreased in
right-sided procedures (RR 0.54, 95% CI 0.32e0.91,
p ¼ .020), in those patients taking aspirin and clopidogrel
prior to the procedure (as compared with any other anti-
platelet regimen, RR 0.59, 95% CI 0.36e0.98, p ¼ .042), in
smokers, and in those with a less severe index event. In the
sensitivity analysis, the model was reconstructed excluding
patients in whom a stent was not deployed. In this analysis,
the use of an open-cell stent conferred higher risk (RR 1.92,
95% CI 1.11e3.33, p ¼ .019). The results of this model are
given in Table 5. The antiplatelet regimen was not adjusted
for in this model as it was no longer a statistically signiﬁcant
predictor in this subset of patients after adjustment for the
stent design variable (p ¼ .30). There was no evidence of an
association between CPD type and risk of an event in the
sensitivity analysis excluding patients in whom a CPD was
not used (data not shown). Patients whose procedure was
carried out in an experienced centre, with a closed-cell
stent and CPD, who received aspirin and clopidogrel anti-
platelet therapy, and who were receiving treatment for
hyperlipidaemia did not have a statistically signiﬁcantly
lower risk of the outcome than other patients (RR 0.61, 95%
CI 0.28e1.32, p ¼ .21).DISCUSSION
Summary
The risk of stroke, MI, or death within 30 days of CAS in ICSS
was signiﬁcantly higher in older patients, those undergoing
a left-sided procedure, in non-smokers, in patients nottaking the combination of aspirin and clopidogrel, and in
those with a more severe index event. An analysis of pa-
tients in whom a stent was deployed demonstrated a
doubling of the risk of the composite event in those
receiving an open cell design stent compared with a closed
cell design.Research in context
The study adds to emerging evidence that CAS is less safe in
older patients. Individual patient data meta-analysis of the
three large European trials of CAS versus CEA (ICSS, the
Endarterectomy Versus Angioplasty in patients with Symp-
tomatic Severe carotid Stenosis (EVA-3S) trial6 and the
Stent-Protected Angioplasty versus Carotid Endarterectomy
(SPACE) trial7 found that although risks of stroke or death
within 120 days were similar in patients allocated to CAS or
CEA in patients under the age of 70 years, the risk of CAS
was twice that of CEA in patients over 70 with no reduction
in the severity of events experienced by this age group.8
CREST showed a similar effect of age.9 It has now been
shown that this effect is related to an increasing risk of
stenting with increasing age. Age should therefore be taken
into account when selecting patients for the procedure.
Stent design also had a strong inﬂuence on risk of stent
deployment in other trials. A higher risk of ipsilateral stroke
or ipsilateral stroke death was found in patients treated
with an open cell stent design in the SPACE study (OR 2.13,
95% CI 1.07e3.76),10 and similar trends are found in large
observational studies.11 Our current observations in the
largest randomized trial of stenting for symptomatic ste-
nosis conﬁrm this ﬁnding. This effect of stent design may be
more pronounced in symptomatic patients due to the un-
stable nature of recently complicated atheromatous plaque;
closed-cell stents have a smaller open area between cell
struts and therefore greater coverage of the atheromatous
lesion.
Cerebral protection devices were introduced in the
assumption that they would reduce cerebral embolism
during stent deployment. A systematic review of the results
of case series comparing older data with results after the
introduction of CPDs appeared to conﬁrm this assump-
tion,12 but the results could also have reﬂected other im-
provements in technique and patient selection over time. In
keeping with the latter possibility, the current analysis has
shown no evidence that CPD use in ICSS protected against
stroke, MI, or death within 30 days of the procedure. The
results are in keeping with the results of the ICSS MRI
substudy which demonstrated a 2.7-fold higher risk of new
ischaemic brain lesions on post-treatment diffusion-
weighted (DWI) brain MRI in patients treated in centres
with a policy of CPD use.13 In contrast to these ﬁndings in
ICSS, the EVA-3S trial issued a clinical alert after ﬁnding that
the 30-day risk of stroke in patients undergoing unprotected
CAS was nearly four times that of patients undergoing
protected CAS in the ﬁrst 80 patients to be randomized.14
However, this difference is unlikely to explained by the
use of a CPD since only two strokes in those treated without
Risk of Stroke, MI or Death after Carotid Stenting 333a CPD occurred on the day of the procedure. Two small
randomized trials of CAS with and without ﬁlter-type CPDs,
which were the predominant type used in ICSS, have re-
ported results. One trial in the United States showed no
reduction in DWI-MRI lesions post-procedure in the CPD
group,15 the other UK-based trial demonstrated an increase
in both new ischaemic brain lesions post-procedure and
procedural particulate microemboli as detected by trans-
cranial Doppler in the CPD group.16 Newer types of de-
vices, including ﬂow reversal systems, might be more
effective. However, the data do not support the routine use
of a distal ﬁlter CPD during stenting procedures.
The reduction in 30-day neurological complications in
patients taking ‘dual’ antiplatelet therapy has been
described before,17 and reinforces the recommendation
that all CAS patients receive aspirin and clopidogrel prior to
the procedure where appropriate. The ﬁnding that current
smoking was associated with a lower complication rate is
difﬁcult to explain and has not been described elsewhere. It
is therefore possible that this is a chance ﬁnding or that
there may be residual confounding.
The chosen combined outcome measure encapsulates
serious complications that patients and doctors wish to
avoid and was chosen to match the primary outcome
measure used in the previous analysis of short-term out-
comes in ICSS.1 However, some variables such as choice of
stent design, might be expected to have a much greater
impact on stroke rates than on MI or non-stroke death. In
practice, the results of the analysis indicate the risk factors
for stroke during CAS, given that were only three MI or non-
stroke deaths compared to 58 stroke events included in the
combined outcome event used.Limitations of the analysis
CAS is a rapidly developing procedure, and newer CPD and
stent types have become available since the ﬁrst patient
enrolment in ICSS. In some patients, information regarding
baseline risk factors was unavailable and some procedures
were abandoned before the deployment of either a CPD or
stent, limiting the inclusion of these patients and variables
in a multivariable model. Multiple comparisons without
statistical correction raise the possibility of obtaining a Type
I (false positive) error. This is not a randomized comparison
of stenting technique or perioperative processes of care,
and it is possible that unmeasured confounders are asso-
ciated with the risk of stroke, MI, or death. The limited
number of events in the patient group limited the number
of variables supported in a multivariable model.
CONCLUSIONS
Selection of patients for CAS should take into account risk
factors for peri-procedural stroke including symptoms, the
patient’s age and side of the procedure. Stenting should be
used with caution in older patients. These results favour the
use of closed-cell stent design, without the addition of a
cerebral protection device, and reinforce the need for dual
antiplatelet therapy with aspirin and clopidogrel. Increasedpower to further characterize groups of patients at higher
risk or technical procedures associated with an increased
complication rate will be facilitated through combined in-
dividual patient data analyses from recent randomized trials
of carotid stenosis as part of the Carotid Stenosis Trialists
Collaboration (http://www.carotid-trialists.com/).
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